A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
A legfontosabb adatok
- Ki végzi
- A2A Pharmaceuticals Inc.
- Hol
- Charleston, Dallas, Detroit, Fairfax, Houston és Oklahoma City (Egyesült Államok)Mind a 6 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1. fázis
- Résztvevők
- 86 fő, tervezett
- Kezdés
- 2023. nov. 2.
- Várható befejezés
- 2028. jan. 27.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- AO-252
- A regiszteradat frissítve
- 2026. augusztus 17.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with advanced solid tumors, with or without spread to the brain, to test the oral drug AO-252. Men with prostate cancer that no longer responds to hormone therapy can also join.
- Életkor
- 18 years and older
- Nem
- All sexes
- A betegség stádiuma
- Solid tumor that has spread or grown locally and cannot be removed by surgery, with or without brain metastases. Must have measurable disease per RECIST v1.1. ECOG performance status of ≤ 1 (fully active or only mild limits). Life expectancy of ≥ 3 months. For prostate cancer: mCRPC adenocarcinoma, without neuroendocrine features or mixed histology. For brain spread: at least one untreated brain lesion ≥0.5 cm (0,2 in) and <3.0 cm (1,2 in), not needing immediate brain treatment.
- Korábbi kezelés
- Cancer must have come back or not responded after at least 1 line of whole-body therapy for metastatic disease (not counting melanoma). Prostate cancer: surgical or medical castration, and progression on at least 1 prior AR-targeted drug (abiraterone acetate, apalutamide, enzalutamide, darolutamide) and/or at least 1 prior chemotherapy (e.g., docetaxel). No anticancer therapy within 3 weeks or 5 half-lives. Prior SRS radiosurgery is allowed if it does not overlap the current target areas.
- Biomarker vagy leletérték
- TP53 mutation or loss in the tumor (not required for prostate cancer). Prostate cancer: PSA of ≥ 2 ng/mL and testosterone less than 50 ng/dL.
A részvétel fő kizáró okai
- Brain metastases causing symptoms that need treatment, or cancer spread to the brain lining (leptomeningeal disease)
- Another cancer within 3 years, apart from some treated skin cancers or in-situ carcinoma
- Pregnant or breastfeeding
- Unable to take pills by mouth because of bowel or stomach disease
- HIV without effective treatment and undetectable virus, or active hepatitis B or untreated hepatitis C
A regiszter feltételei, szó szerint
Mind a 26 feltétel megnézéseKevesebb
Ki vehet részt
- Adults ≥ 18 years of age
- Patient has histologically or cytologically confirmed metastatic or locally advanced unresectable solid tumors with TP53 mutation/loss and with/without brain metastasis. Patients must have relapsed/be refractory to at least 1 line of systemic therapy in the metastatic setting (excluding melanoma)
- Prostate cancer:; mCRPC with histologic confirmation of adenocarcinoma. mCRPC with neuroendocrine features or mixed histology are excluded; Patients will be enrolled irrespective of the TP53 status; Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL; Is surgically or medically castrated, with testosterone levels of less than 50 ng/dL; Patients who progressed on at least 1 prior novel androgen receptor AR-targeted therapy (that is, abiraterone acetate, apalutamide, enzalutamide, darolutamide), and or at least 1 prior systemic chemotherapy (e.g., docetaxel)
- Solid tumors with brain metastasis:; Histologically or cytologically confirmed metastatic or locally advanced unresectable solid tumors excluding melanoma with TP53 mutation/loss and tumor must have relapsed/be refractory to at least 1 line of systemic therapy. Untreated brain metastases not requiring immediate local CNS therapy; Previously treated brain metastases with progression of previous lesions or new lesions, but not requiring immediate local CNS therapy; At least one measurable untreated brain lesion ≥0.5 cm and <3.0 cm in the longest axis; Prior SRS radiosurgery (must be completed within 7 days of study treatment initiation) is allowed as long as the previous treatment volume does not overlap with the current targets
- Measurable disease per RECIST v1.1 criteria. For mCRPC patients, tumor response will be evaluated using RECIST version 1.1 (soft tissue) and PCWG-3 criteria (bone) and efficacy endpoints will also include radiographic progression-free survival (rPFS), PSA50 response and PSA progression
- Adequate bone marrow reserve, cardiac, liver, and renal function:; Absolute neutrophil count (ANC) ≥ 1,500/mm3; Platelet count ≥ 100,000/mm3; Hemoglobin ≥ 9 g/dL; Bilirubin ≤ 1.5 × upper limit of normal (ULN) or direct bilirubin ≤ ULN for patients with total bilirubin levels >1.5 × ULN; Alanine aminotransferase (ALT, SGPT) and aspartate aminotransferase (AST, SGOT) ≤ 2.5 × ULN (≤ 5 × ULN if liver metastases are present); INR ≤ 1.5 × ULN unless patient is receiving anticoagulant therapy and PT or aPTT is within therapeutic range of intended use of anticoagulants; Creatinine clearance ≥ 60 mL/min (by Cockroft Gault formula)
- Female patients of child-bearing potential must have a negative serum pregnancy test and use at least 1 form of acceptable birth control method listed below as approved by the Investigator before initiating study treatment and for 3 months after the last dose of study drug; Sterilization; Any hormonal contraceptives (non-CYP 3A4 inhibitors) associated with inhibition of ovulation; IUD (intrauterine device) or intrauterine hormone releasing system
- Male patients must be sterilized or use a form of barrier contraception, such as condoms with spermicide, during the study and for 3 months after the last dose of study drug
- Life expectancy of ≥ 3 months
- Ability to provide written informed consent
- An Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
Ki nem vehet részt
- Presence of any serious concomitant systemic disorders incompatible with the study in the opinion of the Investigator (e.g., uncontrolled congestive heart failure, active infection)
- Radiation therapy to > 30% of bone marrow within 3 months before study entry
- Patient has received systemic anticancer therapy within 3 weeks or 5 half-lives, whichever is shorter
- Patients must have recovered from all AEs due to previous therapies to ≤ Grade 1 or baseline
- Known HIV-infected patients unless on effective anti-retroviral therapy with an undetectable viral load within 6 months and no opportunistic infection within the past 12 months, or b. Known or suspected hepatitis B if active infection (patients with chronic hepatitis B infection must have an undetectable HBV viral load on suppressive therapy, if indicated; positive surface antibody alone is not an exclusion), or c. Known or suspected hepatitis C infection that has not been treated and cured unless currently on treatment with an undetectable viral load
- Administration of strong or moderate cytochrome (CYP) 3A4 inhibitors and inducers within 14 days or 5 half-lives (whichever is shorter) prior to the administration of study drug
- Patients with symptomatic brain metastases requiring treatment and/or leptomeningeal disease
- Patients with a previous history of another malignancy (other than cured basal cell or squamous cell carcinoma of the skin or cured in-situ carcinoma) within 3 years of study entry
- Patients with gastrointestinal tract disease causing the inability to take oral medication (e.g., swallowing difficulties, malabsorption syndromes, extensive small bowel resection [> 100cm], gastric bypass surgery)
- Known human immunodeficiency virus, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (excluding cured HBV and/or cured HCV infection)
- Patients with clinically significant autoimmune disease, either currently present of present within 2 years, including a current requirement for systemic immunosuppressive therapy equivalent to > 10 mg/prednisone daily (local immunosuppressive therapy such as inhaled or topical corticosteroids is allowed)
- Any of the following conditions (on-study testing is not required):
- Patients with abnormal or clinically significant electrocardiogram (ECG) abnormality, including but not limited to a confirmed corrected QT interval using Fridericia's formula (QTcF) > 470 msec
- Patients with uncontrolled pleural effusions, pericardial effusion, or ascites that do not resolve
- Pregnant or breast-feeding patients or any patient with child-bearing potential not using adequate contraception
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- Hollings Cancer Center - MUSCCharleston, Egyesült ÁllamokContact: Recruitment CoordinatorRésztvevőt keres
- Mary Crowley Cancer ResearchDallas, Egyesült ÁllamokContact: Angela HotchkissRésztvevőt keres
- Karmanos Cancer InstituteDetroit, Egyesült ÁllamokContact: Ira Winer, MD (principal investigator)Résztvevőt keres
- NEXT Oncology- VirginiaFairfax, Egyesült ÁllamokContact: Anthony YoungRésztvevőt keres
- The University of Texas M. D. Anderson Cancer CenterHouston, Egyesült ÁllamokContact: Guoxin FengRésztvevőt keres
- Oklahoma UniveristyOklahoma City, Egyesült ÁllamokContact: Christina CaldwellRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
A vizsgálat 2 csoportja
- Part 1: Dose EscalationA vizsgált kezelés
Participants will be assigned to dose levels.
Kezelés: AO-252
- Part 2: Dose ExpansionA vizsgált kezelés
After doses are decided in Part 1, participants entering part 2 will be assigned to a dose level.
Kezelés: AO-252
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 1, Open-Label, Dose-escalation and Dose-Expansion Study Evaluating AO-252, a Protein-Protein Interaction Inhibitor of TACC3, in Patients With Advanced Solid Tumors With or Without Brain Metastases
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2026. augusztus 17.